Cantel Medical Corp. (NYSE:CMD) to report quarterly earnings at $0.61 per share on revenue of $238.07 million before the opening bell.
Fourth quarter 2019 net sales were $239.5M, up 4.6% compared to the prior year. Excluding the impact from foreign currency, net sales increased by 5.6%, driven by organic growth of 3.4%, and the impact from acquisitions net of dispositions of 2.2%.
Fourth-quarter 2019 GAAP earnings per diluted share decreased 48.1% to $0.21, compared to GAAP earnings per diluted share of $0.41 in the prior year period. GAAP earnings per diluted share were negatively impacted by acquisition-related expenses in the quarter.
Fourth-quarter 2019 Non-GAAP earnings per diluted share increased 3.0% to $0.63, compared to Non-GAAP earnings per diluted share of $0.62 in the prior year period.
This year the Company has made specific investments in the business which impacted both GAAP and Non-GAAP earnings. The impact to GAAP and Non-GAAP diluted EPS from these investments was estimated to be a negative $0.09 per diluted share in the current quarter compared to the prior-year period.
The fourth quarter ended with cash of $44.5 million and gross debt of $233 million, while generating adjusted EBITDAS of $47.1 million in the quarter, up 6.0%.
Said CEO George Fotiades, "We are pleased to report strong sales growth in both our Medical and Dental segments. Medical sales increased 9.8% organically, with total sales growth of 8.2%. Organic growth returned in Dental with an increase of 0.8%, compared to a record fourth quarter in the prior fiscal year.”
Cantel shares plummeted $4.22, or 5%, in the first hour of trade Monday to $80.80.
